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Abstract
Background/Aim. Age-related macular degeneration
(AMD) is a leading cause of the loss of central visual acuity
in population older than 70 years. We can distinguish wet
and dry form of AMD. The aim of the study was to present
our early results in treatment of the wet (neovascular) form
of AMD with intravitreal administration of bevacizumab.
Methods. The study included 39 patients. Each patient un-
derwent a complete ophthalmological examination, fluores-
cein angiography (FA) and optical coherence tomography
(OCT). All the patients received 1.25 mg of intravitreal
bevacizumab (0.05 mL of commercial phial of Avastin®).
The total of three doses was given with a one-month inter-
val between doses. Results.  Among 39 patients, 24 were
women and 15 men. The average best corrected visual acu-
ity (BCVA) was improved from 0.09 before the therapy to
0.24 after the administration of all the three doses of
bevacizumab (p  <  0.001). The average central macular
thickness (CMT) measured by OCT was improved from
474 μm in the beginning to 341 μm after the administration
of all the three doses of the drug (p < 0.001). There were no
side effects. Conclusions. Our short-term experience indi-
cates that intravitreal administration of three doses of
bevacizumab in one-month intervals between the doses
leads to a significant reduction of macular edema and im-
provement of BCVA in patients with neovascular AMD.
Key words:
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Apstrakt
Uvod/Cilj. Starosna degeneracija žute mrlje (age-related macu-
lar degeneration – AMD) glavni je uzroÿnik gubitka centralne
oštrine vida kod osoba starijih od 70 godine. Postoje vlažna i
suva forma AMD. Cilj rada bio je prikaz rezultata u leÿenju
vlažne (neovaskularne) forme AMD intravitrealnom prime-
nom bevacizumaba. Metode. U radu je prikazano 39 boles-
nika. Kod svakog bolesnika uraĀen je kompletan oftalmološki
pregled, fluoresceinska angiografija (FA) i optiÿka koherentna
tomografija (optical coherence tomography – OCT). Svi bolesnici
su primili intravitrealno 1,25 mg bevacizumaba (0,05 mL
komercijalnog preparata Avastin®). Ukupno su date tri doze
u razmacima po mesec dana izmeĀu doza. Rezultati. Od 39
bolesnika, 24 osobe bile su ženskog, a 15 muškog pola. Pro-
seÿna najbolje korigovana vidna oštrina (best corrected visual
acuity – BCVA) popravila se sa 0,09 pre terapije, na 0,24 na-
kon primene sve tri doze bevacizumaba (p < 0,001). Prose-
ÿna centralna debljina makule (central  macular thickness –
CMT), merena OCT aparatom, popravila se sa 474 μm na
poÿetku leÿenja na 341 μm nakon primene sve tri doze leka
(p < 0,001). Nije bilo nikakvih neželjenih efekata. Zaklju-
ÿak. Naše kratkoroÿno iskustvo govori u prilog tome da
bevacizumab, primenjen intravitrealno u tri doze u razma-
cima po mesec dana, dovodi do znaÿajnog smanjenja edema
makule i poboljšanja BCVA kod bolesnika sa neovaskular-
nom AMD.
Kljuÿne reÿi:
antitela, monoklonska; angiogeneza, inhibitori;
makularna degeneracija; horoidalna
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Introduction
Age-related macular degeneration (AMD) is a leading
cause of the loss of central visual acuity in population older
than 70 years. We can distinguish wet and dry form of AMD.
Wet or exudative (neovascular) form is characterized by the
presence of a choroidal neovascular membrane (CNV) which
is related to higher retinal blood vessel permeability and
neoangiogenesis. One of the underlying causes of these vas-
cular changes is the activity of an isoform of vascular endo-
thelial growth factor (VEGF) called VEGF-A.
VEGF-A presents in various isoforms (VEGF121,
VEGF145, VEGF165, VEGF189, VEGF206 )
 1. All these iso-
forms can be bound by bevacizumab which is its advantage
over other available VEGF-A inhibitors (pegaptanib, ranibi-
zumab). Molecular weight of bevacizumab (149 kDa), longer
half-life and ability to reach subretinal space through the cir-
culation explain its better results in the management of neo-
vascular AMD.
Bevacizumab (Avastin
®) is a monoclonal VEGF-anti
body approved for intravenous use in the management of
colorectal carcinoma. Off-label intravenous administration of
this medication in neovascular AMD treatment was firstly
published by Michels et al. in 2005
 2. Shortly after this many
other articles about intravitreal administration of bevacizu-
mab in neovascular AMD treatment have followed 
3–8.
The aim of this article was to present our initial results
in monitoring macular edema reduction and its correlation
with visual acuity after intravitreal administration of bevaci-
zumab to patients with neovascular AMD.
Methods
The participants in our study were 39 patients with sub-
foveolar CNV related to AMD.  Intravitreal administration of
bevacizumab was approved by the Ethics Committee of the
Military Medical Academy (MMA). All the patients were in-
formed about off-label usage of this medication, about possi-
ble side effects and complications but also about potential
benefit from this treatment. All the patients signed a written
consent form prior to drug administration. Every patient re-
ceived 1.25 mg of bevacizumab (0.05 mL of commercial
phial of Avastin 
® intravitreally). Three doses of bevacizu-
mab were applied at one-month intervals. The patients were
followed up on first, seventh and thirtieth day. A complete
ophthalmological examination was performed on each pa-
tient, including best corrected visual acuity (BCVA), fluo-
rescein angiography (FA), and optical coherence tomography
(OCT). Visual acuity and OCT were performed at each con-
trol examination, while FA was only performed during the
initial examination and then one month following the third
bevacizumab dose.
Best-corrected visual acuity, originally expressed in
meters, was converted into logarithm of the minimum angle
of resolution (LogMAR) for more accurate analyses. For
statistical analysis we used the Friedman ANOVA test and
Wilcoxon test with p < 0.001 considered highly statistically
significant.
Results
We analyzed 39 patients; among them 24 were woman
and 15 were man. The average age was 73.5 (64–83) years.
Visual acuity and OCT were measured prior to the interven-
tion and followed up at regular check-ups on the 7th and
30th day following the intervention. The average visual acu-
ity before the intervention was 0.09. After three months and
three monthly doses of bevacizumab applied over that pe-
riod, the average visual acuity was 0.24 (p < 0.001).  One
month after the first dose, BCVA was 0.20 (p < 0.001) and
one month after the second dose it was 0.22 (p < 0.05). In
our study BCVA of 34 (87.2%) eyes improved and of 5
(12.8%) eyes remained the same. We had no cases of visual
acuity worsening. Seven (17.95%) eyes showed visual acuity
improvement of one row and 13 (33.3%) eyes improved by
two rows. Eventually, 5 (12.82%) eyes showed improvement
of the stunning five rows (Figure 1, Table 1).
Table 1
The average best corrected visual acuity (BCVA) after the
administration of bevacizumab
Time (months) Average BCVA (m) p
00 . 0 9
1 0.20 < 0.001
20 . 2 2 <  0 . 0 5
3 0.24 < 0.001
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Fig. 1 – Change in best corrected visual acuity (BCVA) after the administration of three monthly doses of bevacizumab
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The average central macular thickness (CMT) measured
by OCT prior to the intervention was 474 μm, and three
months following three doses of bevacizumab it was 341 μm
(p < 0.001). After the administration of all the three doses of
bevacizumab, the average macular edema reduction was 132
μm. Every eye showed an improvement in CMT reduction,
although in 5 eyes BCVA did not improve (Figures 2 and 3,
Table 2).
Table 2
Average central macular thickness (CMT) measured by op-
tical coherence tomography (OCT) after administration of
bevacizumab
Time (months) Average CMT (μm) p
0 474
1 402 < 0.001
2 374 < 0.001
3 341 < 0.001
Discussion
Most of the eyes treated with bevacizumab in this study
showed attempted improvement, both morphological and
functional response. Our results confirm a significantly
higher reduction of macular edema and improvement of
BCVA in patients with neovascular AMD.
While systemic bevacizumab administration was related
to increased risk for complications and adverse effects such
as gastrointestinal bleeding, thromboembolism and arterial
hypertension, intravitreal bevacizumab administration ap-
plied in our study proved to be free of any systemic and local
complications.
There are several anti-VEGF medications registered for
intravitreal administration worldwide. Pegaptanib was the
first in this group to be accepted for wet AMD form treat-
ment. Shortly after this one, ranibizumab was registered for
intravitreal administration. Ranibizumab (Lucentis
®) was ap-
proved for intravitreal administration by the American Food
and Drug Administration in 2006. This decision was based
on the results presented in MARINA and ANCHOR studies.
These studies proved ranibizumab efficiency 
3, 9.
As previously mentioned, Avastin
® was introduced in
ophthalmology in 2005 and soon after that several studies
about its efficiency in treatment of wet AMD form followed.
Fong et al. 
10 reported in their study that there was no statisti-
cally significant difference regarding BCVA improvement
between groups receiving bevacizumab and ranibizumab.
After the reports about similar efficiency of these two medi-
cations we decided to use significantly less expensive
bevacizumab in our study.
Our study was based on updated results, published
worldwide, about intravitreal bevacizumab administration. A
precise dose of the used medication and timeline in the
treatment protocol varied among the studies. Most frequently
used doses were 1.25 mg and 2.5 mg of bevacizumab. Based
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Fig. 2 – Change in central macular thickness (CMT) (μm) measured by optical coherence tomography (OCT) after the
administration of three monthly doses of bevacizumab.
Before administration of  bevacizumab
CMT= 550 μm
One month after administration of
bevacizumab CMT=390 μm
Fig. 3 – Central macular thickness (CMT) measured by optical coherence tomography (OCT) before and after
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on the published data that imply no statistically significant
difference between the two doses in BCVA improvement
and CMT reduction, we chose the lower one for our study.
Ghazi et al.
11 applied bevacizumab only once and then
decided about continuing with the next dose based on clini-
cal evaluation. In studies published by Bashshur et al. 
5 and
Averya et al.
 4 bevacizumab was applied three times in one-
month intervals between the doses. It is considered that anti
VEGF effect of bevacizumab starts after approximately 24
h from administration and persists for 2–3 weeks 
12. Conrad
et al. 
8 in 2008 considered that bevacizumab effect might
last up to 8 weeks after administration. We assume that this
periodic administration provides better VEGF inhibition
and, consequently, faster CNV retrieval. This was our rea-
son to accept three doses protocol with one month between
doses.
Conclusion
Today many ophthalmologists worldwide use anti-
VEGF treatment, particularly bevacizumab for neovascular
AMD.
In our study we used three doses of the drug with one-
month period between each one. Results showed a signifi-
cant difference in improving visual acuity and reducing
macular edema. It is also important to point out that we did
not have any complications in this study.
Still, the decision which protocol of administration is
the best one remains uncertain. For this reason we believe
that summing up all our experiences may bring us one step
closer to more decisive criteria and most effective protocol
for neovascular AMD treatment with intravitreal bevacizu-
mab administration.
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